Active surveillance for favorable-risk prostate cancer: What are the results and how safe is it?

Current Urology Reports

Volumn 8, Issue 5, 2007, Pages 341-344

  Klotz, Laurence ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; NOTE; PROSTATE CANCER;

AGED; ANDROGEN ANTAGONISTS; BIOPSY, NEEDLE; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; OBSERVATION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34848834163     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-007-0027-3     Document Type: Note

References (30)

1. Welch HG , Schwartz LM, Woloshin S.: Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. JNCI 2005, 97:1132-1137.
2. Sakr WA, Haas GP, Cassin BF, et al.: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993, 150:379-385.
3. Jemal A, Tiwari RC, Murray T, et al.: Cancer Statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
4. Etzioni R, Penson DF, Legler JM, et al.: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002, 94:981-990.
5. D'Amico AV, Whittington R, Schultz D, et al.: Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol 1997, 158:1422-1426.
6. Albertsen P, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101.
7. Albertsen PC, Hanley JA, Barrows GH, et al.: Prostate cancer and the Will Rogers phenomenon. Natl Cancer Inst 2005, 97:1248-1253.
8. Hanash K, Utz DC, Cook EN, et al.: Carcinoma of the prostate: a 15-year followup. J Urol 1972, 107:450-453.
9. Johansson J, Holmberg L, Johansson S, et al.: Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997, 277:467-471.
10. Lerner S, Seale-Hawkins C, Carlton CE, Scardino PT: The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 1991, 146:1040-1045.
11. Handley R, Carr TW, Travis D, et al.: Deferred treatment for prostate cancer. Br J Urol 1998, 62:249-253.
12. Adolfsson J, Rönström L, Löwhagen T, et al.: Deferred treatment in clinically localized low-grade prostate carcinoma: the experience from a prospective series at the Karolinska Hospital. J Urol 1994, 69:1757-1760.
13. Waaler G, Stenwig AE: Prognosis of localised prostatic cancer managed by "watch and wait" policy. Br J Urol 1993, 72:214-219.
14. Whitmore W, Warner JA, Thompson IM.: Expectant management of localized prostatic cancer. Cancer 1991, 67:1091-1096.
15. George NJ: Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet 1998, 1:494-494.
16. Aus G, Hugosson I, Norlén L: Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995, 154:460-465.
17. Sandblom G, Dufmants M, Varenhorst E: Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 2000, 56:442-447.
18. Klotz L: Active surveillance for prostate cancer: for whom? J Clin Oncol 2005, 23:8165-8169.
19. Parker C: Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004, 5:101-106.
20. McGregor M., Hanley JA, Boivin JF, et al.: Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998, 159:1368-1372.
21. Presti JC Jr: Prostate biopsy: how many cores are enough? Urol Oncol 2003, 21:135-140.
22. Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224.
23. Pound C, Partin AW, Eisenberger MA, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
24. Draisma G, Boer R, Otto SJ, et al.: Lead times and overdetection due to PSA screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003, 95:868-878.
25. Törnblom M, Eriksson H, Franzén S, et al.: Lead time associated with screening for prostate cancer. Int J Cancer 2004, 108:122-129.
26. Choo R, Klotz L, Danjoux C, et al.: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002, 167:1664-1669.
27. Choo R, DeBoer G, Klotz L, et al.: PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001, 50:615-620.
28. Klotz L: Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006, 24:46-50.
29. Bill-Axelson A, Holmberg L, Ruutu M, et al.: Radical prostatectomy versus watchful waiting. N Engl J Med 2005, 352:1977-1984.
30. Steineck G, Helgesen F, Adolfsson J, et al.: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002, 347:790-796.